Global, multicenter, randomized, phase ii trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
Academic Article
Overview
MeSH Major
Adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols
Liver Neoplasms
Pancreatic Neoplasms
abstract
This randomized, phase II study achieved its primary end point, demonstrating an improved 6-month SR with addition of AGS-1C4D4 to gemcitabine among patients with previously untreated, metastatic pancreatic adenocarcinoma. ClinicalTrials.gov identifier: NCT00902291.